These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. ; Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315 [TBL] [Abstract][Full Text] [Related]
12. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan. Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694 [TBL] [Abstract][Full Text] [Related]
14. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey. Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714 [TBL] [Abstract][Full Text] [Related]
18. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Lanari M; Vandini S; Arcuri S; Galletti S; Faldella G Clin Dev Immunol; 2013; 2013():359683. PubMed ID: 23840240 [TBL] [Abstract][Full Text] [Related]
19. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Esposito S; Abu-Raya B; Bonanni P; Cahn-Sellem F; Flanagan KL; Martinon Torres F; Mejias A; Nadel S; Safadi MAP; Simon A Front Immunol; 2021; 12():708939. PubMed ID: 34456918 [TBL] [Abstract][Full Text] [Related]
20. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Paes B; Mitchell I; Li A; Lanctôt KL Eur J Pediatr; 2012 May; 171(5):833-41. PubMed ID: 22203430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]